Clonal Hematopoiesis of Indeterminate Potential in Chronic Thromboembolic Pulmonary Hypertension : A Multicenter Study
BACKGROUND: The pathogenesis of chronic thromboembolic pulmonary hypertension (CTEPH) is multifactorial and growing evidence has indicated that hematological disorders are involved. Clonal hematopoiesis of indeterminate potential (CHIP) has recently been associated with an increased risk of both hematological malignancies and cardiovascular diseases. However, the prevalence and clinical relevance of CHIP in patients with CTEPH remains unclear.
METHODS: Using stepwise calling on next-generation sequencing data from 499 patients with CTEPH referred to 3 centers between October 2006 and December 2021, CHIP mutations were identified. We associated CHIP with all-cause mortality in patients with CTEPH. To provide insights into potential mechanisms, the associations between CHIP and inflammatory markers were also determined.
RESULTS: In total, 47 (9.4%) patients with CTEPH carried at least 1 CHIP mutation at a variant allele frequency of ≥2%. The most common mutations were in DNMT3A, TET2, RUNX1, and ASXL1. During follow-up (mean, 55 months), deaths occurred in 22 (46.8%) and 104 (23.0%) patients in the CHIP and non-CHIP groups, respectively (P<0.001, log-rank test). The association of CHIP with mortality remained robust in the fully adjusted model (hazard ratio, 2.190 [95% CI, 1.257-3.816]; P=0.006). Moreover, patients with CHIP mutations showed higher circulating interleukin-1β and interleukin-6 and lower interleukin-4 and IgG galactosylation levels.
CONCLUSIONS: This is the first study to show that CHIP mutations occurred in 9.4% of patients with CTEPH are associated with a severe inflammatory state and confer a poorer prognosis in long-term follow-up.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:81 |
|---|---|
| Enthalten in: |
Hypertension (Dallas, Tex. : 1979) - 81(2024), 2 vom: 18. Jan., Seite 372-382 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Chao [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clonal hematopoiesis of indeterminate potential |
|---|
| Anmerkungen: |
Date Completed 19.01.2024 Date Revised 19.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1161/HYPERTENSIONAHA.123.22274 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366073354 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366073354 | ||
| 003 | DE-627 | ||
| 005 | 20240119231955.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/HYPERTENSIONAHA.123.22274 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1264.xml |
| 035 | |a (DE-627)NLM366073354 | ||
| 035 | |a (NLM)38116660 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Chao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clonal Hematopoiesis of Indeterminate Potential in Chronic Thromboembolic Pulmonary Hypertension |b A Multicenter Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.01.2024 | ||
| 500 | |a Date Revised 19.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: The pathogenesis of chronic thromboembolic pulmonary hypertension (CTEPH) is multifactorial and growing evidence has indicated that hematological disorders are involved. Clonal hematopoiesis of indeterminate potential (CHIP) has recently been associated with an increased risk of both hematological malignancies and cardiovascular diseases. However, the prevalence and clinical relevance of CHIP in patients with CTEPH remains unclear | ||
| 520 | |a METHODS: Using stepwise calling on next-generation sequencing data from 499 patients with CTEPH referred to 3 centers between October 2006 and December 2021, CHIP mutations were identified. We associated CHIP with all-cause mortality in patients with CTEPH. To provide insights into potential mechanisms, the associations between CHIP and inflammatory markers were also determined | ||
| 520 | |a RESULTS: In total, 47 (9.4%) patients with CTEPH carried at least 1 CHIP mutation at a variant allele frequency of ≥2%. The most common mutations were in DNMT3A, TET2, RUNX1, and ASXL1. During follow-up (mean, 55 months), deaths occurred in 22 (46.8%) and 104 (23.0%) patients in the CHIP and non-CHIP groups, respectively (P<0.001, log-rank test). The association of CHIP with mortality remained robust in the fully adjusted model (hazard ratio, 2.190 [95% CI, 1.257-3.816]; P=0.006). Moreover, patients with CHIP mutations showed higher circulating interleukin-1β and interleukin-6 and lower interleukin-4 and IgG galactosylation levels | ||
| 520 | |a CONCLUSIONS: This is the first study to show that CHIP mutations occurred in 9.4% of patients with CTEPH are associated with a severe inflammatory state and confer a poorer prognosis in long-term follow-up | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a clonal hematopoiesis of indeterminate potential | |
| 650 | 4 | |a hypertensionm, pulmonary | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a outcome assessment | |
| 650 | 4 | |a pulmonary thromboembolism | |
| 700 | 1 | |a Zhou, Yu-Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Lian, Tian-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Ruo-Nan |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Jing-Si |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Yin-Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Si-Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xian-Mei |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Lu-Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Bao-Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Li-Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jia |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Zhi-Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jing-Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Lan |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Xi-Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Lian-Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Chun-Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Ze-Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Jing, Zhi-Cheng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hypertension (Dallas, Tex. : 1979) |d 1983 |g 81(2024), 2 vom: 18. Jan., Seite 372-382 |w (DE-627)NLM000456136 |x 1524-4563 |7 nnns |
| 773 | 1 | 8 | |g volume:81 |g year:2024 |g number:2 |g day:18 |g month:01 |g pages:372-382 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/HYPERTENSIONAHA.123.22274 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 81 |j 2024 |e 2 |b 18 |c 01 |h 372-382 | ||